Monocarboxylate transporters in the brain and in cancer☆

Monocarboxylate transporters (MCTs) constitute a family of 14 members among which MCT1–4 facilitate the passive transport of monocarboxylates such as lactate, pyruvate and ketone bodies together with protons across cell membranes. Their anchorage and activity at the plasma membrane requires interact...

Full description

Bibliographic Details
Main Authors:	Pérez-Escuredo, Jhudit, Van Hée, Vincent F., Sboarina, Martina, Falces, Jorge, Payen, Valéry L., Pellerin, Luc, Sonveaux, Pierre
Format:	Online
Language:	English
Published:	Elsevier Pub. Co 2016
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4990061/

id	pubmed-4990061
recordtype	oai_dc
spelling	pubmed-49900612016-10-01 Monocarboxylate transporters in the brain and in cancer☆ Pérez-Escuredo, Jhudit Van Hée, Vincent F. Sboarina, Martina Falces, Jorge Payen, Valéry L. Pellerin, Luc Sonveaux, Pierre Article Monocarboxylate transporters (MCTs) constitute a family of 14 members among which MCT1–4 facilitate the passive transport of monocarboxylates such as lactate, pyruvate and ketone bodies together with protons across cell membranes. Their anchorage and activity at the plasma membrane requires interaction with chaperon protein such as basigin/CD147 and embigin/gp70. MCT1–4 are expressed in different tissues where they play important roles in physiological and pathological processes. This review focuses on the brain and on cancer. In the brain, MCTs control the delivery of lactate, produced by astrocytes, to neurons, where it is used as an oxidative fuel. Consequently, MCT dysfunctions are associated with pathologies of the central nervous system encompassing neurodegeneration and cognitive defects, epilepsy and metabolic disorders. In tumors, MCTs control the exchange of lactate and other monocarboxylates between glycolytic and oxidative cancer cells, between stromal and cancer cells and between glycolytic cells and endothelial cells. Lactate is not only a metabolic waste for glycolytic cells and a metabolic fuel for oxidative cells, but it also behaves as a signaling agent that promotes angiogenesis and as an immunosuppressive metabolite. Because MCTs gate the activities of lactate, drugs targeting these transporters have been developed that could constitute new anticancer treatments. This article is part of a Special Issue entitled: Mitochondrial Channels edited by Pierre Sonveaux, Pierre Maechler and Jean-Claude Martinou. Elsevier Pub. Co 2016-10 /pmc/articles/PMC4990061/ /pubmed/26993058 http://dx.doi.org/10.1016/j.bbamcr.2016.03.013 Text en © 2016 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
repository_type	Open Access Journal
institution_category	Foreign Institution
institution	US National Center for Biotechnology Information
building	NCBI PubMed
collection	Online Access
language	English
format	Online
author	Pérez-Escuredo, Jhudit Van Hée, Vincent F. Sboarina, Martina Falces, Jorge Payen, Valéry L. Pellerin, Luc Sonveaux, Pierre
spellingShingle	Pérez-Escuredo, Jhudit Van Hée, Vincent F. Sboarina, Martina Falces, Jorge Payen, Valéry L. Pellerin, Luc Sonveaux, Pierre Monocarboxylate transporters in the brain and in cancer☆
author_facet	Pérez-Escuredo, Jhudit Van Hée, Vincent F. Sboarina, Martina Falces, Jorge Payen, Valéry L. Pellerin, Luc Sonveaux, Pierre
author_sort	Pérez-Escuredo, Jhudit
title	Monocarboxylate transporters in the brain and in cancer☆
title_short	Monocarboxylate transporters in the brain and in cancer☆
title_full	Monocarboxylate transporters in the brain and in cancer☆
title_fullStr	Monocarboxylate transporters in the brain and in cancer☆
title_full_unstemmed	Monocarboxylate transporters in the brain and in cancer☆
title_sort	monocarboxylate transporters in the brain and in cancer☆
description	Monocarboxylate transporters (MCTs) constitute a family of 14 members among which MCT1–4 facilitate the passive transport of monocarboxylates such as lactate, pyruvate and ketone bodies together with protons across cell membranes. Their anchorage and activity at the plasma membrane requires interaction with chaperon protein such as basigin/CD147 and embigin/gp70. MCT1–4 are expressed in different tissues where they play important roles in physiological and pathological processes. This review focuses on the brain and on cancer. In the brain, MCTs control the delivery of lactate, produced by astrocytes, to neurons, where it is used as an oxidative fuel. Consequently, MCT dysfunctions are associated with pathologies of the central nervous system encompassing neurodegeneration and cognitive defects, epilepsy and metabolic disorders. In tumors, MCTs control the exchange of lactate and other monocarboxylates between glycolytic and oxidative cancer cells, between stromal and cancer cells and between glycolytic cells and endothelial cells. Lactate is not only a metabolic waste for glycolytic cells and a metabolic fuel for oxidative cells, but it also behaves as a signaling agent that promotes angiogenesis and as an immunosuppressive metabolite. Because MCTs gate the activities of lactate, drugs targeting these transporters have been developed that could constitute new anticancer treatments. This article is part of a Special Issue entitled: Mitochondrial Channels edited by Pierre Sonveaux, Pierre Maechler and Jean-Claude Martinou.
publisher	Elsevier Pub. Co
publishDate	2016
url	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4990061/
_version_	1613629978986938368

Monocarboxylate transporters in the brain and in cancer☆

Similar Items